Every program is personalized, physician-led, and monitored closely for your success
Renal protection with glucagon-like peptide type 1 receptor agonists In CVOTs of arGLP1 renal outcomes were prespecified as key secondary outcomes in 4 studies done with liraglutide, subcutaneous semaglutide, dulaglutide, and efpeglenatide,58,59,63,64 or were collected as safety parameters in other studies.60 Overall, the prevalence of CKD stage 3 in these studies was low (2030%) (Table 1)
The compounded semaglutide products provided by Noom are not reviewed by FDA for safety, efficacy, or quality
Given the investigational nature of both peptides, particularly their combination, careful consideration of sourcing, administration, and monitoring is essential for responsible and ethical research
In Part 1, well explore key considerations for identifying appropriate GLP-1 candidates and highlight the importance of setting realistic weight loss expectations